Stock Market Update

[BRIEFING.COM] The major averages continue to trade modestly higher. 

Neurocrine Biosciences (NBIX 130.00, -1.60, -1.22%)  is trading lower after announcing its acquisition of Soleno Therapeutics (SLNO 52.20, +12.70, +32.17%) for $52/share in cash, representing a 34% premium to SLNO's April 2 close.

While the deal adds a compelling growth asset, the stock's negative reaction likely reflects investor concerns around deal cost, execution risk, and the strategic expansion beyond NBIX's core neuroscience focus. The transaction is expected to be financed through a combination of cash on hand and new debt, which may also be weighing on sentiment given balance sheet considerations.